Depomed Inc (DEPO.OQ)
6.53USD
2:59pm EDT
$-0.04 (-0.61%)
$6.57
$6.56
$6.56
$6.39
19,844
113,049
$7.15
$4.91
About
Overall
| Beta: | 1.53 |
| Market Cap (Mil.): | $371.23 |
| Shares Outstanding (Mil.): | 56.50 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| DEPO.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 38.06 | 37.87 |
| EPS (TTM): | -0.47 | -- | -- |
| ROI: | -24.12 | 19.42 | 18.70 |
| ROE: | -29.52 | 20.10 | 19.53 |
FDA advisors vote against two drugs for menopausal hot flashes
WASHINGTON - Advisers to the Food and Drug Administration on Monday voted against approval of two drugs designed to reduce the frequency and severity of hot flashes associated with menopause, concluding that neither conferred enough benefit to offset their risk.
UPDATE 3-FDA advisors vote against two drugs for menopausal hot flashes
* U.S. FDA advisory panel votes to reject Depomed's Sefelsa * Panel also rejects Noven Pharmaceuticals menopause drug * Advisors say neither drug confers enough benefit * Depomed shares fall 9.8 percent (Adds panel's rejection of Noven drug) By Toni Clarke WASHINGTON, March 4 - Advisers to the U.S. Food and Drug Administration on Monday voted against approval of two drugs designed to reduce the frequency and severity of hot flashes associated with menopause, concl
BRIEF-Depomed falls after FDA advisory committee rejects menopause drug
NEW YORK, March 4 - Depomed Inc : * Resumes trading down 15.8 percent to $5.50 after FDA advisory committee rejects menopause drug
FDA advisers vote against approval for Depomed's menopause drug
March 4 - Advisers to the U.S. Food and Drug Administration on Monday recommended the agency reject a drug made by Depomed Inc to reduce the frequency and severity of hot flashes associated with menopause.
FDA staff say two non-hormonal hot flashes drugs show some efficacy
- Food and Drug Administration staff said experimental drugs by Depomed Inc and Hisamitsu Pharmaceutical Co Inc showed efficacy in reducing menopausal hot flashes, and highlighted no new risks in comments issued on Thursday.
Competitors
| Price | Change | |
|---|---|---|
| Takeda Pharmaceutical Company Limited (4502.T) | ¥4,635 | +55.00 |
| Shionogi & Co Ltd (4507.T) | ¥2,188 | +146.00 |
| Ranbaxy Laboratories Limited (RANB.NS) | Rs273.10 | +10.75 |
| Pfizer Inc. (PFE.N) | $29.34 | +0.23 |
| Johnson & Johnson (JNJ.N) | $93.94 | +0.17 |
| Merck & Co., Inc. (MRK.N) | $48.38 | -0.20 |
| GlaxoSmithKline plc (GSK.L) | 1,712.50p | 0.00 |
| Bristol Myers Squibb Co. (BMY.N) | $43.79 | -0.20 |
| Bristol Myers Squibb Co. (BMYMP.PK) | -- | -- |
| Teva Pharmaceutical Industries Limited (TEVA.TA) | 13,920.00₪ | -200.00 |
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: S&P Capital IQ Quantitative Report
|
$69.00
|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

